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Abstract
Introduction: Autoantibodies to the Th/To antigen have been described in systemic sclerosis (SSc) and several
proteins of the macromolecular Th/To complex have been reported to react with anti-Th/To antibodies. However,
anti-Th/To has not been clinically utilized due to unavailability of commercial tests. The objective of the present study
is to evaluate the newly developed ELISA and chemiluminescent immunoassay (CLIA) to measure autoantibodies to
Rpp25 (a component of the Th/To complex) using immunoprecipitation (IP) as the reference method.
Methods: The first cohort consisted of 123 SSc patients including 7 anti-Th/To positive samples confirmed by IP.
Additional seven anti-Th/To positive samples from non-SSc patients were also tested. For evaluation of the
QUANTA Flash Rpp25 CLIA (research use only), 8 anti-Th/To IP positives, a cohort of 70 unselected SSc patients and
sera from various disease controls (n = 357) and random healthy individuals (n = 10) were studied.
Results: Anti-Rpp25 antibodies determined by ELISA were found in 11/14 anti-Th/To IP positive but only in 1/156
(0.6%) negative samples resulting in a positive percent agreement of 78.6% (95% confidence interval [CI] 49.2,
95.3%) and a negative percent agreement of 99.4% (95% CI 96.4, 100.0%). To verify the results using a second
method, 53 samples were tested by ELISA and CLIA for anti-Rpp25 reactivity and the results were highly correlated
(rho = 0.71, 95% CI 0.56, 0.81; P < 0.0001). To define the cutoff of the CLIA, anti-Th/To IP positive and negative sera
were tested using the anti-Rpp25 CLIA. At the cutoff selected by receiver operating characteristic (ROC) analysis 8/8
(100.0%) of the anti-Th/To positive sera but only 2/367 (0.5%) of the controls were positive for anti-Rpp25
antibodies. The positive and negative percent agreements were 100.0% (95% CI 63.1, 100.0%) and 99.5% (95% CI
98.0, 99.9%), respectively. In the disease cohorts 2/70 (2.9%) of the SSc patients were positive for anti-Rpp25
antibodies compared to 2/367 (0.5%) of the controls (P = 0.032). ROC analysis showed discrimination between SSc
patients and controls with an area under the curve value of 0.732 (95% CI 0.655, 0.809).
Conclusion: Rpp25 is a major target of autoantibodies to the Th/To autoantigen complex. Further studies are
needed to evaluate the clinical utility of the new assays.
Introduction
Systemic autoimmune rheumatic diseases (SARD) includ-
ing systemic sclerosis (SSc) are characterized by produc-
tion of autoantibodies to intracellular targets [1]. In SSc,
as well as anti-centromere (ACA) [2], anti-topoisomerase
I (topo-I, Scl-70) [3] and anti-RNA polymerase III
antibodies [1], several other autoantibodies have been
described. These include autoantibodies targeting
the PM/Scl complex (also known as the exosome) [4],
U3RNP/fibrillarin [5] and the Th/To autoantigens [6-9].
Anti-Th/To antibodies are one of the specificities that
show homogenous nucleolar staining in indirect immuno-
fluorescence (IIF) antinuclear antibody (ANA) tests
[6,10,11]. In SSc, anti-Th/To has been associated with lim-
ited cutaneous SSc (lcSSc) subset and the reported preva-
lence of anti-Th/To antibodies varies between 1 and 13%
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[6,12,13]. In addition to SSc, a few reports have described
anti-Th/To antibodies in rheumatoid arthritis (RA) and
interstitial lung disease (ILD) [14,15].
The Th/To antigen complex is a multi-protein-RNA
complex (human RNase MRP complex) that consists of
a catalytic RNA and several protein components [7,16].
RNase MRP is a ubiquitously expressed eukaryotic
endoribonuclease that cleaves various RNAs, including
ribosomal, messenger, and mitochondrial RNAs, in a
highly specific fashion [7]. At least ten protein subunits,
Rpp14, Rpp20, Rpp21, Rpp25, Rpp29 (hPop4) [17],
Rpp30 [18], Rpp38 [18], Rpp40, hPop1, and hPop5 are
known [7]. Almost all protein components of the RNase
MRP and the evolutionarily related RNase P complex
have been reported to be the target of autoantibodies in
patients with SARD [7,8,14]. The major autoantigens
have been identified as Rpp25 and hPop1 [7]. Rpp25
(Ribonuclease P protein subunit p25, NP_060263.2) is a
25 kDa protein subunit of RNase P. Historically, anti-
Th/To antibodies have been detected by immunopreci-
pitation (IP) [6]. While some studies tested serological
cohorts, other investigations analyzed samples initially
screened based on nucleolar staining pattern identified
by IIF. Recently, commercial line immunoassays (LIA)
for the detection of anti-Th/To antibodies became avail-
able and were evaluated in two independent studies
[19,20]. In addition, an IP real-time PCR assay has been
developed and evaluated [21].
Although known for over 20 years, little is known
about the clinical association of autoantibodies targeting
the individual components of the Th/To antigen.
Furthermore, anti-Th/To antibodies are rarely used in
routine testing algorithms to aid in the diagnosis and
stratification of SSc. Consequently, we aimed to develop
immunoassays to detect antibodies to a defined single
component (Rpp25) of the Th/To complex and to evalu-
ate the newly developed ELISA and chemiluminescent
immunoassay (CLIA) using IP as a reference method.
Methods
Sera
The first cohort consisted of 123 SSc patients including
seven with anti-Th/To positive samples confirmed by IP,
enrolled in the University of Florida Center for Autoim-
mune Diseases (UFCAD) registry from 2000 to 2012. An
Additional seven anti-Th/To positive samples from non-
SSc patients (two with Raynaud’s phenomenon (RP), one
with pulmonary hypertension, one with interstitial lung
disease (ILD), one with Sjögren’s syndrome (SS), one
with SS and ILD and one with polymyositis) from the
same cohort were also included. For evaluation of
QUANTA Flash Rpp25, 53 sera were selected based on
the serum volume available. Samples from 70 SSc
patients were collected and tested at the University of
Calgary (Canada). Sera collected at INOVA included
rheumatoid arthritis (RA, n = 141), systemic lupus
erythematosus (SLE, n = 67), undifferentiated connective
tissue disease (UCTD, n = 17 samples), osteoarthritis
(OA, n = 47), ankylosing spondylitis (AS, n = 13), poly-
myalgia rheumatica (PMR, n = 20), degenerative spine
disease (n = 6), fibromyalgia (n = 5), psoriasis arthritis
(n = 13), other rheumatological and non-rheumatological
diagnoses (n = 28) and healthy individuals (HI, n = 10).
The diagnoses were established as described before [22]
or according to the standard disease criteria.
The protocol was approved by the Institutional Review
Boards (IRB, Health Research Ethics Board of the Uni-
versity of Calgary and University of Florida). This study
meets and is in compliance with all ethical standards in
medicine, and informed consent was obtained from all
patients according to the Declaration of Helsinki.
Recombinant Rpp25 antigen
The cDNA of Rpp25 was cloned into pET28a(+) (Nova-
gen, Merck, Germany) and the his-tagged protein
expressed in BL21(DE3) cells according to the manufac-
turer’s instructions. Soluble recombinant Rpp25 was
extracted using a detergent and affinity purified using a
nickel column. Purity and immunoreactivity was verified
by SDS Page and Western blot using anti-HIS antibody
(SIGMA # H1029 Monoclonal Anti-poly Histidine anti-
body, diluted 1:3,000) and a pool of 10 anti-Th/To IP posi-
tive sera and one control serum.
Immunoassays
Anti-Rpp25 ELISA
Nunc Immobilizer Amino plates (Thermo Fisher Scienti-
fic, Waltham, MA, USA) were coated with 2 microgram/
ml of Rpp25 antigen in PBS, 50 μl/well 2 h at 22°C for
2 h and blocked with 0.5% bovine serum albumin (BSA)
in NET/NP40 (150 mM NaCl, 2 mM ethylenediaminete-
traacetic acid (EDTA), 50 mM Tris-HCl pH 7.5, 0.3%
NP40) for 1 h. Wells were then incubated with sera
diluted 1:500 in blocking buffer for 1 h at 22°C. After
washing three times by TBS/Tween (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.1% Tween 20), wells were incu-
bated with alkaline phosphatase-conjugated donkey
immunoglobulin (Ig)G F(ab)’2 anti-human IgG (gamma-
chain specific, Jackson ImmunoResearch Laboratories,
Inc. West Grove, PA, USA) diluted 1:1,000 in blocking
buffer for 1 h at 22°C. After washing three times, plates
were developed and the OD405 of each sample was con-
verted into units based on the standard curve using the
SoftMax Pro 4.7 program (Molecular Devices, Sunnyvale,
CA, USA) with four-parameter analysis. The standard
curve was established by 1:5 serial dilutions starting from
1:500 dilution of the prototype serum. The last dilution
to show optical density (OD) clearly above background
was 1:62,500 dilution of the serum, and OD from this
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dilution was defined as one unit. Units were applied to
each dilution as follows, so that the units correlate with
the amount of antibodies; 1:500 dilution, 125 units;
1:2,500, 25 units; 1:12,500, 5 units; 1:62,500, 1 unit;
1:312,500, 0.2 units; 1:1,562,500, 0.04 units. Unit values
lower than 0.2 units were below the interpretable range
of the standard curve and recorded as 0.2 units for data
analysis.
QUANTA Flash(R) Rpp25
The QUANTA Flash Rpp25 assay (research use only,
INOVA Diagnostics Inc., San Diego, CA, USA) is a
novel CLIA that is currently used for research purposes
only and utilizes the BIO-FLASH® instrument (Biokit s.
a., Barcelona, Spain), fitted with a luminometer, as well
as all the hardware and liquid handling accessories
necessary to fully automate the assay. The principle of
the QUANTA Flash assays performed on the BIO-
FLASH instrument has recently been described [23].
The QUANTA Flash assay for this study was developed
using full-length, purified, recombinant human Rpp25
antigen coated onto paramagnetic beads. Prior to use, the
reagent pack containing all the necessary assay reagents
is gently inverted thirty times. The sealed reagent tubes
are then pierced with the reagent pack lid. A patient’s
serum sample is pre-diluted with the BIO-FLASH® sam-
ple buffer in a small disposable plastic cuvette. Small
amounts of the diluted serum, the beads, and the assay
buffer are all combined into a second cuvette, mixed, and
then incubated for 9.5 minutes at 37°C. The magnetized
beads are sedimented using a strong magnet in the wash-
ing station and washed several times followed by addition
of isoluminol-conjugated anti-human IgG and again
incubated 9.5 minutes at 37°C. The magnetized beads are
sedimented and washed repeatedly. The isoluminol con-
jugate is oxidized when sodium hydroxide solution and
peroxide solutions (triggers) are added to the cuvette,
and the flash of light produced from this reaction is mea-
sured as relative light units (RLUs) by the BIO-FLASH®
optical system. The RLUs are proportional to the amount
of isoluminol conjugate that is bound to the human IgG,
which is in turn proportional to the amount of anti-
Rpp25 antibodies bound to the antigen on the beads. Pre-
cision of the assay and stability of the assay components
were verified by precision and stability testing. Total,
repeatability, between-run and between-day precision
were determined by running the control sample in tripli-
cates, two runs per day over three days resulting in
18 values.
Detection of anti-Th/To autoantibodies by
immunoprecipitation
Detection of anti-Th/To was based on IP confirmation
of the 7-2 and 8-2 RNAs by RNA analysis with urea-
PAGE and silver staining (Silver stain plus, Bio-Rad,
Hercules, CA, USA). Specificities were verified using
previously characterized reference sera. Analysis of pro-
teins to determine other SSc autoantibodies recognized
by sera was performed by IP of 35S-methionine radiola-
beled K562 cell extract, SDS-PAGE and autoradiography
as described [6].
Statistical evaluation
The data were statistically evaluated using the Analyse-it
software (Version 1.62; Analyse-it Software, Ltd., Leeds,
UK). The chi-square test, Spearman’s correlation and
Cohen’s kappa test of agreement were carried out to
analyze the agreement between portions, and P-values <
0.05 were considered significant. Receiver-operating
characteristics (ROC) analysis was used to analyze the
discriminatory ability of different immunoassays.
Results
Anti-Rpp25 antibodies in samples characterized by
immunoprecipitation and measured by ELISA
Samples tested for anti-Th/To reactivity by IP were
tested for anti-Rpp25 reactivity by ELISA. The reactivity
to Rpp25 was significantly higher in anti-Th/To IP-posi-
tive than in anti-Th/To IP-negative samples (P <
0.0001) (Figure 1). After ROC analysis, showing an area
under the curve (AUC) value of 0.941 (95% CI 0.833,
1.000), a preliminary cutoff was defined, which yielded a
sensitivity of 78.6% (95% CI 49.2, 95.3%) and a specifi-
city of 99.4% (95% CI 96.4, 100.0%). There was no sig-
nificant difference in the levels of anti-Rpp25 between
anti-Th/To-positive SSc vs. anti-Th/To-positive non-SSc
patients (P = 0.902).
Anti-Rpp25 antibodies measured by chemiluminescent
technology
To verify the results using a second method, a total of 53
samples that were tested by ELISA and QUANTA Flash
CLIA for anti-Rpp25 reactivity showed high correlation
(rho = 0.71, 95% CI 0.56, 0.81; P < 0.0001; see Figure 2).
Next we analyzed the precision of the QUANTA Flash
Rpp25 CLIA, which demonstrated good precision with a
total variation of 6.6% (Table 1). To analyze the prevalence
of anti-Rpp25 antibodies in different cohorts, anti-Th/To-
positive sera (n = 8 identified by IP), unselected SSc sam-
ples (n = 70) and disease and healthy controls (n = 367)
were tested using the anti-Rpp25 assay on the BIO-
FLASH instrument (Figure 3). The anti-Th/To-positive
sera were from four SSc patients, two with RP, one with
SS and one with ILD. There was no significant difference
between the Th/To-positive SSc and non-SSc patients
(P = 0.4857). When comparing anti-Th/To IP-positive
samples and controls by ROC analysis, showing an AUC
value of 0.919 (95% CI 0.919, 1.000), a preliminary cutoff
was defined (10,000 RLU, see Figure 4). At this cutoff 8/8
(100.0%) of the anti-Th/To-positive sera but only 2/367
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Figure 1 Anti-Rpp25 antibodies in Th/To immunoprecipitation (IP)-positive and IP-negative samples measured by enzyme-linked
immunosorbent assay (ELISA). Comparative descriptive analysis is shown in a). In b) the receiver operating characteristic (ROC) analysis shows
good discrimination between anti-Th/To IP-positive patients (n = 14) and controls (anti-Th/To-negative SSc and healthy individuals, n = 156).
AUC, area under the curve.
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Figure 2 Correlation between enzyme-linked immunosorbent assay (ELISA) and chemiluminescent immunoassay (CLIA). The results of
53 samples tested by anti-Rpp25 ELISA and CLIA (QUANTA Flash) showed good agreement (rho = 0.71; P < 0.0001, Spearman correlation test).
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(0.5%) of the controls were positive for anti-Rpp25 antibo-
dies by QUANTA Flash Rpp25 (P < 0.0001). Thus a posi-
tive percent agreement of 100.0% (95% CI 63.1, 100.0%)
and a negative percent agreement of 99.5% (95% CI 98.0,
99.9%) were found. At this cutoff, 2/70 (2.9%) of the sec-
ond cohort of SSc patients were positive for anti-Rpp25
antibodies compared to 2/367 (0.5%) of the controls (P =
0.032). Positive (LR+) and negative (LR-) likelihood ratios
were 5.24 and 0.98, respectively (Table 2). The two control
patients with a positive result had low levels of anti-Rpp25
antibodies and one had RA (RLU = 25,259) and the other
patient had a diagnosis of PR (RLU = 19,561). ROC analy-
sis showed discrimination between SSc patients and con-
trols with AUC values of 0.732 (95% CI 0.655, 0.809).
Discussion
Autoantibodies represent valuable biomarkers in the
diagnosis of SARD, including SSc [1,24]. Almost all pro-
tein components of the RNase MRP and the evolutiona-
rily related RNase P complex have been reported to be
the target of autoantibodies in patients with SARD
[7,14]. In our study we focused on the autoantibody
Table 1 Precision of QUANTA Flash for the detection of anti-Th/To (Rpp25) antibodies
Precision SD (95% CI) Coefficient of variation Claimed SD P
Total 1,665.1 (1124.7-3189.9) 6.6% 3,786.1 0.9919
Repeatability 1,452.0 (1041.2-2396.9) 5.8% 3,786.1 0.9997
Between-run 0.0 0.0%
Between-day 814.9 3.2%
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PMR 
Cohort n (%) Mean SE SD
ThTo pos (n=8) 8 (100) 299347 94849 to 503846 86482 244609
RA (n=141) 1 (0.7) 1112 1 to 1462 177 2104
SLE (n=67) 0 (0) 1301 1161 to 1442 71 577
UCTD (n=17) 0 (0) 1412 882 to 1942 250 1031
OA (n=47) 0 (0) 984 844 to 1124 70 477
AS (n=13) 0 (0) 910 591 to 1228 146 527
PMR (n=20) 1 (5) 1969 11 to 3927 935 4183
DSD (n=6) 0 (0) 469 368 to 570 39 96
FM (n=5) 0 (0) 1261 255 to 2268 363 811
PAs (n=13) 0 (0) 1362 544 to 2180 376 1354
others (n=28) 0 (0) 839 700 to 979 68 359
HI (n=10) 0 (0) 709 635 to 784 33 105
95% CI
Figure 3 Anti-Rpp25 antibodies in samples from anti-Th/To immunoprecipitation (IP)-positive patients, an independent cohort of
patients with systemic sclerosis and controls measured by QUANTA Flash anti-Rpp25. Comparative descriptive analysis is shown of
samples from anti-Th/To IP-positive patients (n = 8), patients with SSc (n = 70) and controls (n = 367) including patients with rheumatoid
arthritis (RA, n = 141), systemic lupus erythematosus (SLE, n = 67), undifferentiated connective tissue disease (UCTD, n = 17), osteoarthritis (OA, n
= 47), ankylosing spondylitis (AS, n = 13), polymyalgia rheumatica (PR, n = 20), degenerative spine disease (n = 6), fibromyalgia (n = 5), psoriasis
arthritis (n = 13), other pathologies (n = 28) and healthy individuals (HI, n = 10). SE, standard error.
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Figure 4 Receiver-operating characteristics (ROC) analysis. a) ROC analysis shows good discrimination between Th/To immunoprecipitation
(IP)-positive patients (n = 8) and controls (n = 367) including rheumatoid arthritis (RA, n = 141), systemic lupus erythematosus (SLE, n = 67),
undifferentiated connective tissue disease (UCTD, n = 17), osteoarthritis (OA, n = 47), ankylosing spondylitis (AS, n = 13), polymyalgia rheumatica
(PMR, n = 20), degenerative spine disease (n = 6), fibromyalgia (n = 5), psoriasis arthritis (n = 13), other pathologies (n = 28) and healthy
individuals (HI, n = 10). b) ROC analysis shows discrimination between SSc (n = 70) and controls (n = 367). AUC, area under the curve; SSc,
systemic sclerosis.
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reactivity to Rpp25, one of the major antigens of the
complex [7].
Our data show that Rpp25 is a major autoantigen tar-
geted by anti-Th/To antibodies, which is consistent with
previous findings [7]. In our cohort of samples, anti-
Rpp25 was detected in approximately 70 to100%
(depending on the assay and cutoff used) of anti-Th/To
reactivity. In the study by van Eenennaam et al. [7],
8/12 (66.7%) anti-Th/To-positive samples immunopreci-
pitated in-vitro transcribed and translated Rpp25. Both
assays used in our study (ELISA and CLIA) showed
good discrimination between anti-Th/To IP-positive and
IP-negative samples and exhibited excellent correlation
with each other. However, the CLIA showed a superior
discrimination (signal to noise ratio) between anti-Th/
To-negative and -positive samples and might represent
the preferred method to detect antibodies to Rpp25.
The high sensitivity of the BIO-FLASH CLIA system is
interesting. There are several technical differences between
the ELISA and the CLIA which might account for the
better discrimination between anti-Th/To-positive and
-negative samples. The BIO-FLASH system uses magnetic
particles that have a significantly higher surface area com-
pared to ELISA plates. On average, the CLIA uses about
5 to10 times more antigen per reaction compared to
ELISA (unpublished data). In addition, the antibody reac-
tion occurs in solution and follows microfluidic kinetics
[25]. The samples from the anti-Th/To-positive RA and
PMR patients did not show a nucleolar staining pattern.
Although they were not tested by IP for anti-Th/To reac-
tivity, it is likely that they represent false positive findings.
Despite those two samples, the specificity of the Rpp25
CLIA is very high (> 99%). Although the reason for the
difference between the anti-Rpp25 CLIA and ELISA
remains speculative and deserves further investigation, the
anti-Th/To (Rpp25) CLIA holds promise to provide a reli-
able alternative method to the radioisotope-based IP assay.
Although anti-Th/To antibodies are uncommon in
samples from patients with SARD, the observation that
anti-Th/To antibodies are mostly detectable in SSc
makes this specificity important in the diagnosis of SSc.
In addition, current multiplex assays [26] and a screening
fluorescence enzyme immunoassay (FEIA) [27] show
satisfactory performance characteristics as an ANA
screening test for mixed connective tissue disease
(MCTD), SS and autoimmune myositis (AIM), but are
not sufficiently sensitive for SSc due to the lack of
nucleolar antigens [28]. An anti-Th/To test may also be
applicable to non-SSc patients such as those with ILD,
since anti-Th/To antibodies have been reported in
around 50% of patients with anti-nucleolar antibody-
positive idiopathic pulmonary fibrosis [10]. The preva-
lence in our unselected cohort of SSc patients was 2.9%,
similar to recent studies (Table 2). Villalta [19] and Bon-
roy [20] found anti-Th/To antibodies in 3.3% and 2.1% of
SSc patients, respectively, but observed lower specificity
(98.7% and 97.8% vs 99.5% in our study).
In a study by Kuwana et al. [14], anti-hPop1 antibodies
were significantly more prevalent in anti-Th/To-positive
SSc patients, compared to anti-Th/To-positive patients
with other types of SARD. In contrast, Rpp30 and Rpp38
were equally targeted by antibodies from SSc and non-SSc
SARD patients. Further studies with additional Th/To
recombinant or purified proteins are required to verify
this finding.
Although known for over 20 years, understanding the
clinical features associated with the anti-Th/To system
requires clarification. Previous studies are mostly consis-
tent in showing its association with lcSSc; however, asso-
ciation with more specific clinical features are somewhat
inconsistent. A small number of anti-Th/To positive
patients, differences in ethnicity and environment, recruit-
ment bias and other types of bias could explain the incon-
sistency [6,8,29-31]. Anti-Th/To antibodies have been
associated with pericarditis and ILD, and they are highly
frequent in intrinsic pulmonary hypertension [6,12]. Com-
pared with the ACA patients, anti-Th/To lcSSc patients
have more subtle cutaneous, vascular, and gastrointestinal
involvement, but more often have certain features typically
seen in diffuse scleroderma, such as pulmonary fibrosis
and scleroderma renal crisis, as well as reduced survival
compared to ACA-positive patients [29]. Like other SSc-
related autoantibodies, in patients with Raynaud’s phe-
nomenon anti-Th/To antibodies are risk factors that are
predictive of emerging SSc [32]. Anti-Th/To-positive
patients demonstrate earlier development of abnormalities
Table 2 Clinical sensitivity and specificity of anti-Th/To antibodies measured by QUANTA Flash Rpp25 vs a commercial
line immunoassay for systemic sclerosis (SSc)
Villalta et al. Bonroy et al. Present study
Method EUROLINE SSc Profile EUROLINE SSc Profile QUANTA Flash Rpp25 (CLIA)
Sensitivity1 7/210 (3.3; 1.3, 6.7) 3/145 (2.1; 0.4, 5.9) 2/70 (2.9; 0.3, 9.9)
Specificity2 148/150 (98.7; 95.2, 99.9) 271/277 (97.8; 95.3, 99.2) 365/367 (99.5; 98.0, 99.9)
LR+ 2.5 0.96 5.24
LR- 0.98 1.0 0.98
1Values are presented as number of positives/number of SSc samples tested (percent positive; 95% CI). 2Values are presented as number of negatives/number of
non-SSc samples tested (percent negative; 95%CI). LR+, positive likelihood ratio; LR-, negative likelihood ratio; CLIA, chemiluminescent assay.
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on nail-fold capillary microscopy (NCM) than ACA-posi-
tive patients [32]. There is some evidence that anti-Th/
To-positive patients are younger and more frequently
male compared to ACA positive patients [6], and it has
been reported that the prevalence of anti-Th/To antibo-
dies might be higher in Caucasian Americans compared to
African and Latin Americans [30]. Although we did not
analyze associations between anti-Rpp25 antibodies and
clinical features in our SARD cohort, it is likely that asso-
ciations of anti-Rpp25 and anti-Th/To are similar based
on the good correlation between anti-Rpp25 antibodies
(by ELISA or CLIA) and anti-Th/To antibodies (by IP).
Although the prevalence of anti-Th/To antibodies is
relatively low, testing for those antibodies might have sig-
nificant value for patient stratification [5,33]. In a previous
study dcSSc and lcSSc subsets were associated with parti-
cular organ manifestations, but in this analysis the clinical
distinction appeared superseded by an antibody-based
classification in predicting some SSc-related complications
[33]. In addition, the discrimination between SSc and con-
trols as measured by the AUC (0.73) derived from ROC
analysis using anti-Th/To (Rpp25) antibody results was
similar to the AUC (0.67) generated by ACA [34].
Further studies using large cohorts of SSc patients such
as those collected by EULAR Scleroderma Trials and
Research (EUSTAR) [35], the Canadian Scleroderma
Research Group (CSRG) [36] or the German Network for
systemic scleroderma [13] and the Australian cohort [37]
are needed to analyze the clinical utility of antibodies to
Rpp25.
Conclusions
Rpp25 is a major target of autoantibodies to the Th/To
autoantigen complex. Autoantibodies to Rpp25 detected
by ELISA and especially CLIA show excellent agreement
with anti-Th/To antibodies detected by IP. The CLIA
represents a quick and reliable method that allows the
detection of anti-Th/To antibodies in as little as 30 min-
utes. Further studies are needed to evaluate the clinical
utility of the new assays.
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